Journal of the American Heart Association

DECEMBER 29, 2023

Journal of the American Heart Association, Ahead of Print. BackgroundHeart failure with preserved ejection fraction ≥50% is prevalent with few evidence‐based therapies. points, whereas usual care worsened by 6.9 points,P<0.001).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Quality of Life Echocardiogram 40

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Obesity was associated with more first and recurrent heart failure events. Overall, 60.9%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Med Page Today

NOVEMBER 18, 2024

(MedPage Today) -- CHICAGO -- The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Quality of Life Heart Failure 52

Circulation

SEPTEMBER 2, 2024

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Quality of Life Article Heart Failure 45

Circulation: Heart Failure

DECEMBER 6, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Heart Failure Quality of Life 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

Heart BMJ

FEBRUARY 12, 2024

Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). To be familiar with the specific considerations of exercise training prescription in specific HF population groups including HF with preserved ejection fraction.

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40

The American Journal of Cardiology

APRIL 15, 2024

Publication date: Available online 13 April 2024 Source: The American Journal of Cardiology Author(s): Syed Imran Ahmed, Jonathan Kenyon, Hayley E. Billingsley, Hannah Salmons, Natalie J. Bohmke, Roshanak Markley, Antonio Abbate, Danielle L. Kirkman, Youngdeok Kim, Salvatore Carbone

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Heart Failure 40

The British Journal of Cardiology

AUGUST 21, 2024

Digoxin has been used in the management of chronic heart failure (HF) and atrial fibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Preserved Ejection Fraction Quality of Life 40

European Journal of Heart Failure

DECEMBER 20, 2023

Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF).

Quality of Life 40

Quality of Life Preserved Ejection Fraction Pacemaker Heart Failure 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life 75

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 for all).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

Circulation: Heart Failure

OCTOBER 23, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Quality of Life Circulation 40

Circulation

NOVEMBER 11, 2024

The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients were divided into two groups based on BB use at trial enrollment. After controlling for potential confounding variables, there were no differences in baseline exercise capacity [peak VO2 (mL/kg/min): 12.1

Quality of Life 40

Quality of Life Preserved Ejection Fraction Exercise Heart Failure 40

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. 6MWD 302.881.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. points (95%CI, 3.3,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

DAIC

MARCH 29, 2024

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Quality of Life Heart Failure Hospital 111

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

Frontiers in Cardiovascular Medicine

NOVEMBER 10, 2024

BackgroundHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coincide. There was no significant improvement of heart failure-related symptoms, echocardiographic parameters and cardiac biomarkers levels. Forty-two were female. ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2,

Preserved Ejection Fraction 52

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. cardiometabolic health CME/CE conference: the 19th Annual CMHC.

CME 103

CME Obesity Heart Failure Biomarkers 103